<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614781</url>
  </required_header>
  <id_info>
    <org_study_id>RYMMA</org_study_id>
    <nct_id>NCT02614781</nct_id>
  </id_info>
  <brief_title>Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea</brief_title>
  <official_title>Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Pharma SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Pharma SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a non-interventional prospective, multicenter, longitudinal study conducted in
      France, among a representative sample of public and/or private birth control centers.

      The aim of the study is to assess, in real-life settings, the success rate of the protocol
      Mifegyne / prostaglandin analogue in patients asking for medical abortion either prior or
      beyond 7 weeks of amenorrhea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>success rate of the protocol Mifegyne and prostaglandin analogue</measure>
    <time_frame>At the follow-up at 2-3 weeks after inclusion</time_frame>
    <description>The success rate will be defined as complete abortion without surgical procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate of the protocol Mifegyne and misoprostol per os.</measure>
    <time_frame>at the follow up at 2-3 weeks after the inclusion</time_frame>
    <description>The success rate will be defined as complete abortion without surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ongoing pregnancy by term.</measure>
    <time_frame>at the follow up at 2-3 weeks after the inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of patients requiring any additional procedures by term.</measure>
    <time_frame>at the follow up at 2-3 weeks after the inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medical abortion using misoprostol</measure>
    <time_frame>at the follow up at 2-3 weeks after the inclusion</time_frame>
    <description>The number of medical abortion using misoprostol will be described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation by patients of pain using a 5 level verbal rating scale</measure>
    <time_frame>at the follow up at 2-3 weeks after the inclusion</time_frame>
    <description>Physician will ask patients to evaluate the pain by a 5 level verbal rating scale. the using of pain killers will be also described</description>
  </secondary_outcome>
  <enrollment type="Actual">892</enrollment>
  <condition>Medical Termination of Pregnancy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        women asking for medical abortion
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult women (≥ 18 years old) with confirmed intra-uterine pregnancy consulting for
             medical termination of pregnancy

          -  Patients for whom the physician decides to use a Mifegyne 600 mg and prostaglandin
             analogue combination for medical abortion

          -  Patients agreeing to participate in the study after having been informed orally by the
             physician and given the information sheet

          -  Informed patients accepting the computer processing of their medical data and their
             right of access and correction

        Exclusion Criteria:

          -  Patients with known hypersensitivity to mifepristone

          -  Patients with known hypersensitivity to prostaglandin analogues (misoprostol or
             gemeprost).

          -  Patients with severe and progressive disease

          -  Patients with ectopic pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène HERMAN-DEMARS, MD</last_name>
    <role>Study Director</role>
    <affiliation>NORDIC PHARMA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

